Mice with HIV nephropathy and selective knockout of the AT1 receptor in podocytes still derive benefit from AT1 blockers, suggesting that these agents may also benefit vascular abnormalities of HIV nephropathy [49]. Here, AGTR1 is linked to HIV-associated nephropathy.